{"id":"NCT01197534","sponsor":"AstraZeneca","briefTitle":"Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.","officialTitle":"(OSKIRA-2): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients With an Inadequate Response to DMARDs","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-09","primaryCompletion":"2013-03","completion":"2013-03","firstPosted":"2010-09-09","resultsPosted":"2014-04-17","lastUpdate":"2014-04-17"},"enrollment":913,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"fostamatinib","otherNames":[]},{"type":"DRUG","name":"fostamatinib","otherNames":[]},{"type":"DRUG","name":"placebo, fostamatinib","otherNames":[]}],"arms":[{"label":"Dosing Regimen A","type":"EXPERIMENTAL"},{"label":"Dosing Regimen B","type":"EXPERIMENTAL"},{"label":"Dosing Regimen C","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to evaluate the effectiveness of two dosing regimens of fostamatinib compared to placebo, in patients with rheumatoid arthritis (RA) who are taking disease modifying anti-rheumatic drug (DMARD) but not responding. The study will last for 1 year.","primaryOutcome":{"measure":"Proportion of Patients With ACR20 at Week 24, Comparison Between Fostamatinib and Placebo","timeFrame":"24 weeks","effectByArm":[{"arm":"FOSTA 100 MG BID PO","deltaMin":39.6,"sd":null},{"arm":"FOSTA 100 MG BID (4 WKS) THEN 150 MG QD PO","deltaMin":39.6,"sd":null},{"arm":"PLACEBO (24 WKS) THEN FOSTA 100 MG BID PO","deltaMin":24.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":9},"locations":{"siteCount":149,"countries":["United States","Canada","Czechia","Germany","India","Israel","Italy","Latvia","Lithuania","Portugal","Romania","Serbia","South Africa","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=421&filename=CSR-D8480C00039.pdf","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1202&filename=CSR-D1700C00004.pdf","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=2264&filename=CSR-1939IL-0551.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":30,"n":308},"commonTop":["HYPERTENSION","DIARRHOEA","NASOPHARYNGITIS","RHEUMATOID ARTHRITIS","NAUSEA"]}}